Dataset: Discovery: Vaginal delivery of Hyaluronic Acid-modified Ginger Extracellular Vesicles (HA-GDEVs) co-functionalized with borneol may penetrate fibrotic endometriotic lesions via CD44 targeting, delivering anti-angiogenic payloads to induce lesion regression without systemic hormonal toxicity. - PathMap Experiment #000135

Dataset: Discovery: Vaginal delivery of Hyaluronic Acid-modified Ginger Extracellular Vesicles (HA-GDEVs) co-functionalized with borneol may penetrate fibrotic endometriotic lesions via CD44 targeting, delivering anti-angiogenic payloads to induce lesion regression without systemic hormonal toxicity. - PathMap Experiment #000135 Description Interactive Data Viewer: Read, View, and Print from Day 1 Use our fully interactive viewer to view, read, and print this research data right from Day 1: https://pathmap.org/viewer.php?id=135 Artificial General Intelligence LLC Claim Evaluated: Discovery: Vaginal delivery of Hyaluronic Acid-modified Ginger Extracellular Vesicles (HA-GDEVs) co-functionalized with borneol may penetrate fibrotic endometriotic lesions via CD44 targeting, delivering anti-angiogenic payloads to induce lesion regression without systemic hormonal toxicity. This dataset contains the raw JSON execution trace, verified verbatim quotes, and MeSH-aligned logic gates generated by PathMap Studio's Veridical Enforcement engine. 🔍 Novel & Overlooked Insights - CD44 is consistently overexpressed in ectopic endometrial tissues, making it a viable receptor for targeted nanotherapeutic strategies. - The use of plant-derived extracellular vesicles, specifically ginger-based, serves as a non-toxic, cost-effective, and biodegradable carrier platform. - Borneol is capable of significantly promoting drug enrichment in specific target tissues when combined with thermosensitive hydrogel or gel-based delivery systems. - Nanocarriers functionalized with HA effectively minimize nonspecific interactions while maintaining near-neutral or slightly negative surface potentials. - Anti-angiogenic therapy targeting the VEGF pathway is a recognized hallmark of non-hormonal endometriosis management. - Surgiflo™ and other hydrogel matrices demonstrate the feasibility of local, sustained drug delivery in surgical or cavity environments. - The co-delivery of natural phytochemicals and chemotherapeutic agents via functionalized nanoplatforms addresses multi-target disease drivers while reducing systemic toxicity. 🧪 Extracted Custom Datapoints 📊 Suggested Experiments - Fabricate HA-GDEVs loaded with an anti-angiogenic payload and compare cellular uptake efficiency in CD44-overexpressing endometriotic stromal cells versus control cells. - Assess the permeability of borneol-embedded HA-hydrogels in a 3D patient-derived endometriosis organoid model. - Evaluate the anti-fibrotic and anti-angiogenic efficacy of the HA-GDEV/borneol system in a rat model of endometriosis. 📊 Suggested Studies - Comparative analysis of HA-GDEV retention time in endometriosis lesions relative to conventional liposomal carriers. - Long-term safety assessment of vaginal delivery of plant-derived nanovesicles on the reproductive tract microbiome. - Pharmacokinetic study of borneol-facilitated drug distribution in endometriotic fibrotic niches. 📊 Swansons Literature Based Discovery Candidates - • Discovered Hypothesis (A to C): Borneol-mediated membrane permeability can enhance the therapeutic delivery of plant-derived extracellular vesicles to deep-seated endometriotic lesions, bridging the gap between existing delivery enhancements for CNS ischemia (Literature A) and local anti-fibrotic treatments (Literature C). • Literature A (Origin): Borneol's capacity for brain targeting and drug enrichment in ischemic stroke treatment (ID: 41429389). • Literature C (Target): Use of ginger-derived nanovesicles and plant-based therapeutics for local treatment of ectopic endometriotic stem cells (ID: 41570918). • The Intersecting Bridge B: Membrane transport and tissue penetration enhancement (facilitated by borneol) and targeted nanoparticle delivery (HA-CD44). • Biological Rationale: Borneol disrupts physical barrier limitations that constrain traditional nanoparticle uptake. By integrating this with the inherent cellular targeting of HA-modified EVs, it is mechanistically plausible that therapeutic efficacy in the dense, fibrotic environment of endometriosis can be significantly improved without relying on systemic doses that cause hormonal suppression. 📊 Contradictions Between Evidences - There is no direct contradiction; the evidences demonstrate a trend of modular design in nanomedicine (targeting ligand + carrier + therapeutic agent), allowing the synthesis of these novel platforms from established components. 📊 Repurposed Solutions - 1. Using anti-angiogenic payloads originally designated for CRC peritoneal metastasis to inhibit endometriosis-associated angiogenesis. 2. Adapting borneol-embedded hydrogel systems for localized drug enrichment in gynecological tissues instead of exclusively the blood-brain barrier. 3. Repurposing probiotic-derived extracellular vesicles as generalized anti-inflammatory carriers for endometriosis. Tags Attractor Table | Extracted Keywords & Entities | |---| | Extracellular Vesicles, _gates_from_extracellular_vesicles, Drug Delivery Systems, _gates_to_drug_delivery_systems, _gates_from_drug_delivery_systems, Remission Induction, _gates_to_remission_induction, _gates_from_remission_induction, Drug-Related Side Effects and Adverse Reactions, _gates_to_drug-related_side_effects_and_adverse_reactions | Run Your Own Analysis PathMap is a patent-pending universal AI workbench designed to eliminate LLM hallucinations in medical research. Generate your own autonomous discovery reports at PathMap.org. Notes Files 135.zip Files (853.7 kB) | Name | Size | Download all | |---|---|---| | md5:c02332cc8a7d4cbac80ce49f68e03b03 | 853.7 kB | Preview Download | Additional details Related works - Is documented by - https://pathmap.org/viewer.php?id=135 (URL)